Latest Artia Global Partners LP Stock Portfolio

Artia Global Partners LP Performance:

2025 Q4: 8.09%YTD: 43.83%2024: 12.25%

Performance for 2025 Q4 is 8.09%, and YTD is 43.83%, and 2024 is 12.25%.

About Artia Global Partners LP and 13F Hedge Fund Stock Holdings

On 2026-02-17, the fund reported it's updated stock portfolio. In the 13F Holdings report, Artia Global Partners LP reported an equity portfolio of $705.8 Millions as of 31 Dec, 2025.

The top stock holdings of Artia Global Partners LP are INSM, , ARGX. The fund has invested 27.2% of it's portfolio in INSMED INC and 11.5% of portfolio in ABIVAX SA.

The fund managers got completely rid off VERONA PHARMA PLC (VRNA), MERUS N V (MRUS) and VERTEX PHARMACEUTICALS INC (VRTX) stocks. They significantly reduced their stock positions in QUEST DIAGNOSTICS INC (DGX), ALNYLAM PHARMACEUTICALS INC (ALNY) and AVIDITY BIOSCIENCES INC (RNA). Artia Global Partners LP opened new stock positions in CIDARA THERAPEUTICS INC (CDTX), VENTYX BIOSCIENCES INC (VTYX) and PALVELLA THERAPEUTICS INC NE. The fund showed a lot of confidence in some stocks as they added substantially to VIKING THERAPEUTICS INC (VKTX), ABIVAX SA and NEWAMSTERDAM PHARMA COMPANY (NAMS).

Artia Global Partners LP Annual Return Estimates Vs S&P 500

Our best estimate is that Artia Global Partners LP made a return of 8.09% in the last quarter. In trailing 12 months, it's portfolio return was 43.83%.

Performance
S&P 500

New Buys

Ticker	$ Bought
cidara therapeutics inc	15,644,300
ventyx biosciences inc	6,284,720
palvella therapeutics inc ne	6,196,460
sionna therapeutics inc	4,926,140
palisade bio inc	4,682,060
prokidney corp	4,118,040
belite bio inc	2,877,520
roivant sciences ltd	2,816,660

New stocks bought by Artia Global Partners LP

Additions

Ticker	% Inc.
viking therapeutics inc	146
abivax sa	33.23
newamsterdam pharma company	29.32
mineralys therapeutics inc	21.73
ionis pharmaceuticals inc	19.96
travere therapeutics inc	14.4
rapport therapeutics inc	7.19

Additions to existing portfolio by Artia Global Partners LP

Reductions

Ticker	% Reduced
quest diagnostics inc	-75.03
alnylam pharmaceuticals inc	-74.83
avidity biosciences inc	-72.71
soleno therapeutics inc	-60.3
argenx se	-58.69
abbvie inc	-50.00
astrazeneca plc	-50.00
bridgebio pharma inc	-50.00

Artia Global Partners LP reduced stake in above stock

Sold off

Ticker	$ Sold
mereo biopharma group plc	-1,958,490
verona pharma plc	-80,887,000
merus n v	-55,878,000
boston scientific corp	-35,771,600
centessa pharmaceuticals plc	-6,464,610
biohaven ltd	-2,401,600
alector inc	-420,492
nektar therapeutics	-6,600,290

Artia Global Partners LP got rid off the above stocks

Sector Distribution

Artia Global Partners LP has about 64.6% of it's holdings in Healthcare sector.

Sector	%
Healthcare	64.6
Others	35.4

Market Cap. Distribution

Artia Global Partners LP has about 42% of it's portfolio invested in the large-cap and mega-cap stocks.

Category	%
UNALLOCATED	35.4
LARGE-CAP	33.8
MID-CAP	11.3
SMALL-CAP	10.5
MEGA-CAP	8.2

Stocks belong to which Index?

About 50.8% of the stocks held by Artia Global Partners LP either belong to S&P 500 or RUSSELL 2000 index.

Index	%
Others	49.2
RUSSELL 2000	41.6
S&P 500	9.2

Top 5 Winners (%)		%
TVTX	travere therapeutics inc	54.1 %
RVMD	revolution medicines inc	52.9 %
	abivax sa	48.0 %
RNA	avidity biosciences inc	41.7 %
LLY	eli lilly & co	38.4 %

Top 5 Winners ($)		$
INSM	insmed inc	38.5 M
	abivax sa	26.3 M
LLY	eli lilly & co	16.8 M
ARGX	argenx se	11.4 M
TRVI	trevi therapeutics inc	10.1 M

Top 5 Losers (%)		%
QURE	uniqure nv	-52.4 %
SLNO	soleno therapeutics inc	-22.0 %
ALNY	alnylam pharmaceuticals inc	-8.0 %
DGX	quest diagnostics inc	-5.6 %
	mineralys therapeutics inc	-3.9 %

Top 5 Losers ($)		$
QURE	uniqure nv	-40.3 M
SLNO	soleno therapeutics inc	-20.0 M
ALNY	alnylam pharmaceuticals inc	-2.5 M
DGX	quest diagnostics inc	-1.7 M
	mineralys therapeutics inc	-0.2 M

Artia Global Partners LP Holdings Map

This heatmap illustrates the top 50 positions within the fund's portfolio.

Current Stock Holdings of Artia Global Partners LP

Artia Global Partners LP has 50 stocks in it's portfolio. About 75% of the portfolio is in top 10 stocks. QURE proved to be the most loss making stock for the portfolio. INSM was the most profitable stock for Artia Global Partners LP last quarter.

Last Reported on: 17 Feb, 2026

Ticker	Namesorted ascending	% Portfolio	Shares Held	$ Value	Type	% Change	Options
ABBV	abbvie inc	0.47	14,500	3,313,100	reduced	-50.00

AGQ	proshares tr ii	4.26	542,119	30,098,400	reduced	-49.56	put

ALEC	alector inc	0.00	0.00	0.00	sold off	-100

ALNY	alnylam pharmaceuticals inc	0.98	17,400	6,919,110	reduced	-74.83

ARGX	argenx se	7.71	64,699	54,408,600	reduced	-58.69

ASND	ascendis pharma a/s	0.54	17,740	3,782,880	reduced	-27.53

AVTX	avalo therapeutics inc	0.11	41,570	754,911	new

AZN	astrazeneca plc	2.48	190,752	17,535,800	reduced	-50.00

BBIO	bridgebio pharma inc	0.22	20,400	1,560,400	reduced	-50.00

BLTE	belite bio inc	0.41	17,989	2,877,520	new

BSX	boston scientific corp	0.00	0.00	0.00	sold off	-100

CDTX	cidara therapeutics inc	2.22	70,824	15,644,300	new

CELC	celcuity inc	0.18	12,900	1,286,650	new

CNTA	centessa pharmaceuticals plc	0.00	0.00	0.00	sold off	-100

DGX	quest diagnostics inc	1.00	40,817	7,082,970	reduced	-75.03

DRUG	bright minds biosciences inc	0.37	33,407	2,607,080	new

EYPT	eyepoint pharmaceuticals inc	1.99	767,098	14,014,900	reduced	-38.96

INSM	insmed inc	27.18	1,102,210	191,829,000	reduced	-24.73	put

IONS	ionis pharmaceuticals inc	1.62	144,376	11,421,600	added	19.96

IREN	iren limited	0.00	0.00	0.00	sold off	-100